Axogen (AXGN) news
Recent news
Axogen, Inc.: BofA global research initiates coverage with buy rating; price objective $52
AInvest Wire · 3d agoAxogen, Inc.: Truist Securities cuts target price to $53 from $60
Truist Securities has revised its price target for Axogen, Inc. (NASDAQ: AXGN) from $60 to $53, while maintaining a "Buy" rating . This adjustment follows a series of recent developments, including Axogen’s acquisition of BioCircuit Technologies for $200 million, which added NerveTape—a…
AInvest Wire · Oct 1, 2026AXogen, Inc.: Truist Securities cuts target price to $53 from $60
AInvest Wire · Oct 1, 2026Axogen shares down 5% premarket after announcing public offering of $208.7 mln at discounted price of $42.5 per share; co to buy Biocircuit for $200 mln
AInvest Wire · Sep 10, 2026Axogen prices offer of 4.91M share at $42.50/shr
Axogen Inc. has announced the pricing of its common stock offering, with 4.91 million shares priced at $42.50 per share[1]. This offering is part of the company’s ongoing efforts to raise capital for general corporate purposes and potential strategic opportunities. The transaction is expected to…
AInvest Wire · Sep 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.